RSV
The ability of recombinant MVA-BN® to stimulate durable
antibody production in newborns has not been seen with other highly
attenuated vaccine vectors or licensed vaccines and is considered
novel and an exciting opportunity to improve existing childhood
vaccines and to develop vaccines for diseases such as Respiratory
Syncytial Virus (RSV) that currently have no licensed vaccine.
These properties of MVA-BN® that allow the vaccination of
newborns led Bavarian Nordic to develop its childhood vaccines
program with a measles vaccine candidate as a proof-of-concept
vaccine i.e. demonstrate that an MVA-BN® based vaccine could
induce protective immune responses in children younger than 12
months old. The measles vaccine candidate was chosen as the lead
product, because there is a clear unmet medical need for more
effective measles vaccines for use in children below 1 year of age
in sub-Saharan Africa and South East Asia where the measles virus
is still endemic and significant measles related morbidity and
mortality still exists. This has allowed the rapid development and
testing of MVA-BN® Measles vaccine in the paediatric
population.
